Yazar "Müftüoglu, E" seçeneğine göre listele

Listeleniyor 1 - 5 / 5
  • [ X ]
    Öğe
    All-trans retinoic acid
    (Medimond S R L, 2000) Ayyildiz, O; Aybak, M; Tiftik, N; Müftüoglu, E
    The introduction of all-trans retinoic acid (ATRA) has further changed the manage-ment of acute promyelocytic leukemia (APL). After using of ATRA, the rate of early death and relapse has decreased dramatically. From February 1997 to March 2000, 12 consecutive patients with APL were treated with ATRA at an oral dose of 45mg/m(2)/d alone or in combination with chemotherapy. In 11 cases treated with ATRA alone, 11 (100%) achieved complete remission (CR) between 35-68 days. The other patient treated with ATRA+Daunorubicin died from central nervous system hemorrhage on the fourth day of treatment. The side effects were relatively mild as compared with chemotherapy. Retinoic acid syndrome was seen in two patients and successfully treated with dexamethasone. Among 11 patients closely followed after CR, 1 died at first relapse. In conclusion; ATRA has been able to induce a very high CR rate in newly diagnosed APL and has less toxic and tolerable side effects.
  • [ X ]
    Öğe
    Hodgkin's disease variant of Richter's transformation -: A case report
    (Humana Press Inc, 2002) Isikdogan, A; Ayyildiz, O; Büyükbayram, H; Müftüoglu, E
    Hodgkin's disease rarely develops in patients with B-chronic lymphocytic leukemia. Patients developing Hodgkin's disease after the diagnosis of chronic lymphocytic leukemia have been called the Hodgkin's disc, ease variant of Richter's transformation. We present a 62-yr-old man with a 17-mo history of chronic lymphocytic leukemia, who clinically and hematologically on remission was admitted to our clinic because of rapidly developing right cervical lymphadenopathy. He was diagnosed with lymph node biopsy as a mixed-cellularity Hodgkin's disease.
  • [ X ]
    Öğe
    Meropenem monotherapy for empiric treatment of febrile neutropenic cancer patients
    (Medimond S R L, 2000) Ayyildiz, O; Iskakdogan, A; Bolaman, Z; Müftüoglu, E
    Empirical antibacterial therapy should be administered to all neutropenic cancer patients with fever or clinical evidence of infection even in the absence of fever. A total of fifty cancer patients with 72 neutropenic episodes were enrolled in the study. Twenty-one (29%) episodes had a microbiologically defined infection, 20 (28%) a clinically defined infection and the remaining 31 (43%) had unexplained fever. 72 episodes initially treated with meropenem 1 g i.v. every 8 h. Gram negative pathogens were 11 (52%) predominated over gram positive isolates were 7 (33%). The success rate without adjustment was 29% in gram positive group and 91% in gram negative group. There were no reports of drug-related nausea/ vomiting or seizures. One patient with AML died of gram positive sepsis resistant to treatment. In conclusion,meropenem monotherapy seemed effective and side effects were tolerable for the treatment of febrile neutropenic cancer patients.
  • [ X ]
    Öğe
    Ogilvie's syndrome in patient with multiple myeloma
    (Pacini Editore, 2002) Göral, V; Uyar, A; Müftüoglu, E
    [Abstract Not Available]
  • [ X ]
    Öğe
    Treatment of advanced chronic lymphocytic leukemia by fludarabine
    (Medimond S R L, 2000) Ayyildiz, O; Tiftik, N; Bolaman, Z; Müftüoglu, E
    Ten patients with B-cell chronic lymphocytic leukemia (CLL), aged 55-72 years, 9 male and 1 female, were treated with fludarabine. Fludarabine is the most active agent for treatment of CLL. All patients were previously treated with alkylating agent-based regimen. Fludarabine was administered for 5 consecutive days 25 mg/m(2)/d and repeated 4-weekly. The response rate was 40% with 1 complete response and 3 partial responses. However, four patients achieved stable disease and 2 progressed. The median survival for responders was 18 months and for non-responders 8 months. Our patients tolerated the fludarabine treatment extremely well. Myelosupression was seen in eight patients. In a total of 37 treatment courses 5 febrile episodes were registered in 4 patients and successfully treated with empirical antibiotic regimen. In conclusion, fludarabine is effective in CLL patients refractory to first-line chemotherapy.